Johnson & Johnson (JNJ) advances after identifying a lead COVID-19 vaccine candidate Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Johnson & Johnson (JNJ) up 3.5% after identifying a lead COVID-19 vaccine candidate, with two back-ups, which will progress into the first manufacturing steps
- Abbott (ABT) up 10% after receiving emergency use authorization from the FDA for the fastest available molecular point-of-care test for the detection of novel coronavirus
- Sanofi (SNY) up 2% after announcing the first patient outside of the U.S. has been treated as part of a global clinical program evaluating Kevzara in patients hospitalized with severe COVID-19
- Plus Therapeutics (PSTV) up 63% after entering into a definitive agreement to license multiple rare cancer drug product candidates from private Texas-based radiotherapeutic company NanoTx Therapeutics
- Owens & Minor (OMI) up 35% after backing FY20 EPS outlook
- IMV Inc. (IMV) up 7% after providing update on its DPX-COVID-19 vaccine
DOWN AFTER EARNINGS -
LOWER -
- Axsome Therapeutics (AXSM) down 15% after disclosing STRIDE-1 trial did not reach statistical significance on the Week 6 primary endpoint on MADRS
- AG Mortgage (MITT) down 25% after suspending its dividend and receiving notifications from several financing counterparties of alleged events of default under their financing agreements
Symbols:
JNJ ABT SNY PSTV OMI HEXO AXSM MITT Keywords: Fly Intel, Wall Street, Top Stories, Stocks